TUBA1B and neoplasm: For instance, it has been observed to impact immune cell infiltration within the tumor microenvironment of liver hepatocellular carcinoma (LIHC) and influence the responsiveness to immunotherapy, thereby significantly affecting their prognosis8,9, potentially attributed to TUBA1B overexpression, which has been linked to paclitaxel resistance in LIHC patients10.